CMX521
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C13H17N5O5 |
| Molar mass | 323.309 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
CMX521 is an antiviral drug discovered by Chimerix, which was developed for the treatment of norovirus, though it also shows efficacy against related viral diarrheas such as rotovirus and some sapoviruses, astroviruses and adenoviruses. It is a nucleoside analogue which acts as an inhibitor of viral RNA-dependant RNA polymerase.[1][2][3]
See also
[edit]References
[edit]- ^ Bassetto M, Van Dycke J, Neyts J, Brancale A, Rocha-Pereira J (February 2019). "Targeting the Viral Polymerase of Diarrhea-Causing Viruses as a Strategy to Develop a Single Broad-Spectrum Antiviral Therapy". Viruses. 11 (2): 173. doi:10.3390/v11020173. PMC 6409847. PMID 30791582.
- ^ Netzler NE, Enosi Tuipulotu D, White PA (May 2019). "Norovirus antivirals: Where are we now?". Medicinal Research Reviews. 39 (3): 860–886. doi:10.1002/med.21545. PMC 7168425. PMID 30584800.
- ^ Ebenezer O, Jordaan MA, Damoyi N, Shapi M (December 2020). "Discovery of Potential Inhibitors for RNA-Dependent RNA Polymerase of Norovirus: Virtual Screening, and Molecular Dynamics". International Journal of Molecular Sciences. 22 (1): 171. doi:10.3390/ijms22010171. PMC 7795727. PMID 33375298.
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |